XML 85 R74.htm IDEA: XBRL DOCUMENT v3.25.3
SEGMENT REPORTING (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue $ 17,110,425 $ 12,411,048 $ 45,568,655 $ 40,202,238
Cost of Sales (14,507,807) (11,204,186) (39,752,424) (36,894,502)
GROSS PROFIT 2,602,618 1,206,862 5,816,231 3,307,736
General and administrative expenses (2,040,341) (1,782,957) (5,009,528) (4,591,620)
Salaries (1,919,950) (1,317,782) (4,828,412) (4,030,823)
Sales and marketing expenses (64,794) (41,848) (114,655) (326,291)
Depreciation and amortization (377,911) (304,139) (1,052,212) (937,000)
Stock-based compensation     1,730,233 1,103,200
Net profit/(loss) before Income Taxes (5,352,890) (2,182,534) (8,999,055) (6,639,935)
Cost of Sales 14,507,807 $ 11,204,186 39,752,424 $ 36,894,502
Other [Member]        
Revenue 405   405  
Cost of Sales 0   0  
GROSS PROFIT 405   405  
General and administrative expenses (582,551)   (1,221,333)  
Salaries (326,655)   (979,841)  
Sales and marketing expenses (33,120)   (33,120)  
Research and development costs (18,337)   (108,603)  
Net finance costs (308,159)   (385,912)  
Segment profit / (loss) (1,268,417)   (2,728,404)  
Depreciation and amortization (36,454)   (108,174)  
Stock-based compensation (570,602)   (1,730,233)  
Non-cash interest (201,447)   (364,550)  
Fair value adjustments (2,486,762)   (2,620,573)  
Foreign currency adjustments (234,778)   (63,716)  
Other income and expenses (5,577)   (233,941)  
Net profit/(loss) before Income Taxes (4,804,037)   (7,849,591)  
Research and development costs 18,337   108,603  
Cost of Sales 0   0  
Total Segment [Member]        
Revenue 17,110,425   45,568,655  
Cost of Sales (14,507,807)   (39,752,424)  
GROSS PROFIT 2,602,618   5,816,231  
General and administrative expenses (1,469,739)   (3,279,295)  
Salaries (1,919,950)   (4,828,412)  
Sales and marketing expenses (64,794)   (114,655)  
Research and development costs (18,337)   (108,603)  
Net finance costs (568,452)   (947,260)  
Segment profit / (loss) (1,438,655)   (3,461,994)  
Depreciation and amortization (377,911)   (1,052,212)  
Stock-based compensation (570,602)   (1,730,233)  
Non-cash interest (201,447)   (364,550)  
Fair value adjustments (2,486,762)   (2,620,573)  
Foreign currency adjustments (271,937)   346,412  
Other income and expenses (5,577)   (115,905)  
Net profit/(loss) before Income Taxes (5,352,890)   (8,999,055)  
Research and development costs 18,337   108,603  
Cost of Sales 14,507,807   39,752,424  
Wholesale [Member]        
Revenue 14,574,914   40,608,665  
Cost of Sales (13,240,183)   (37,626,788)  
GROSS PROFIT 1,334,731   2,981,877  
General and administrative expenses (191,273)   (514,158)  
Salaries (517,261)   (1,381,174)  
Sales and marketing expenses (116)   (971)  
Research and development costs 0   0  
Net finance costs (184,070)   (605,818)  
Segment profit / (loss) 442,011   479,756  
Depreciation and amortization (67,464)   (171,020)  
Stock-based compensation 0   0  
Non-cash interest 0   0  
Fair value adjustments 0   0  
Foreign currency adjustments 207   168,639  
Other income and expenses 0   11,563  
Net profit/(loss) before Income Taxes 374,754   488,938  
Research and development costs 0   0  
Cost of Sales 13,240,183   37,626,788  
Pharma manufacturing [Member]        
Revenue 412,603   1,213,562  
Cost of Sales (70,393)   (208,777)  
GROSS PROFIT 342,210   1,004,785  
General and administrative expenses (193,755)   (499,702)  
Salaries (684,859)   (1,410,704)  
Sales and marketing expenses (181)   (911)  
Research and development costs 0   0  
Net finance costs 0   0  
Segment profit / (loss) (536,584)   (906,532)  
Depreciation and amortization (159,552)   (451,149)  
Stock-based compensation 0   0  
Non-cash interest 0   0  
Fair value adjustments 0   0  
Foreign currency adjustments 241,489   241,489  
Other income and expenses 0   95,318  
Net profit/(loss) before Income Taxes (454,648)   (1,020,874)  
Research and development costs 0   0  
Cost of Sales 70,393   208,777  
Nutraceuticals and Pharmaceuticals [Member]        
Revenue 2,122,503   3,746,023  
Cost of Sales (1,197,231)   (1,916,859)  
GROSS PROFIT 925,272   1,829,164  
General and administrative expenses (502,160)   (1,044,103)  
Salaries (391,175)   (1,056,693)  
Sales and marketing expenses (31,377)   (79,653)  
Research and development costs 0   0  
Net finance costs (76,223)   44,470  
Segment profit / (loss) (75,665)   (306,814)  
Depreciation and amortization (114,441)   (321,869)  
Stock-based compensation 0   0  
Non-cash interest 0   0  
Fair value adjustments 0   0  
Foreign currency adjustments (278,855)   0  
Other income and expenses 0   11,155  
Net profit/(loss) before Income Taxes (468,960)   (617,528)  
Research and development costs 0   0  
Cost of Sales $ 1,197,231   $ 1,916,859